It is assumed that platelets in diseased conditions share similar properties to platelets in healthy conditions, although this has never been examined in detail for myocardial infarction (MI). We examined platelets from patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) compared with platelets from healthy volunteers to evaluate for differences in platelet phenotype and function. Platelet activation was examined and postreceptor signal transduction pathways were assessed. Platelet-derived plasma biomarkers were evaluated by receiver operator characteristic curve analysis. Maximum platelet activation through the thromboxane receptor was greater in STEMI than in NSTEMI but less through proteaseactivated receptor 1. Extracellular-signal related-kinase 5 activation, which can activate platelets, was increased in platelets from subjects with STEMI and especially in platelets from patients with NSTEMI. Matrix metalloproteinase 9 (MMP9) protein content and enzymatic activity were several-fold greater in platelets with MI than in control. 
INTRODUCTION
More than fifty years ago, it was discovered that aspirin inhibits platelet activation by preventing platelet thromboxane synthesis and adenosine diphosphate (ADP) secretion-mechanisms that amplify platelet activation via surface receptors. [1] [2] [3] Based on those discoveries, dual antiplatelet therapy, consisting of aspirin and a P2Y12 receptor antagonist, is the standard of care in the treatment of ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). [4] [5] [6] Failure of platelet antagonists to have their anticipated effect in some patients has been attributed to single nucleotide polymorphisms in genes encoding proteins responsible for metabolism of P2Y12 antagonists, 7, 8 for cyclooxygenase enzymatic activity, in aspirin transporters, and in aspirin absorption. [9] [10] [11] These studies all suggest that a personalized approach to antiplatelet therapy should be considered when a patient's treatment trajectory deviates from the expected path. Longitudinal studies acknowledge that patients with STEMI have enjoyed improved outcomes over the last 2 decades with advances in percutaneous intervention without much change in mortality for NSTEMI. 12 A recent study indicates patient mortality for NSTEMI has failed to improve since 2010 in spite of delivery of care consistent with established guidelines, including appropriate utilization of percutaneous revascularization procedures. 13, 14 Reasons for this difference in long-term mortality observed in patients after STEMI compared with NSTEMI may include fundamental differences in platelet biology for each condition. Whether circulating platelets in diseased conditions are phenotypically and functionally similar to platelets in healthy subjects is an underexplored area of investigation. 15, 16 We and others reported that platelet extracellular-signal-regulated kinase 5 (ERK5) alters the platelet phenotype in murine models of thrombotic and ischemic disease and in platelets exposed to redox stress. 17 , 18 Hu et al recently demonstrated that platelet receptor and postreceptor signaling change in diabetic platelets with consequent resistance to clopidogrel. 19 These studies suggest that greater attention should be paid to changes in platelet postreceptor signal transduction pathways in diseased conditions.
Examining the true platelet phenotype in coronary artery disease is an extraordinarily difficult task given that coronary instrumentation and nonuniform blood collection techniques alter platelet function. After myocardial infarction (MI), patients are placed on aspirin and a P2Y12 receptor antagonist, making it impossible to assess contributions of individual platelet receptor signaling pathways. In an effort to address this limitation, we isolated platelets from patients with MI after aspirin monotherapy and before the patient undergoing coronary angiography or receiving a loading dose of a P2Y12 receptor antagonist. We carefully examined platelet receptor signaling and platelet biomarkers in MI, and compared them with platelets isolated from healthy individuals. The goal was to assess the true functional contribution of platelet receptors for which oral antiplatelet medications are available. Using this information, we attempted to evaluate whether the platelet phenotype in STEMI differs from NSTEMI, offering a possible mechanistic explanation for differences in long-term outcomes.
MATERIALS AND METHODS
Study population and design. This study was approved by the University of Rochester Research Subjects Review Board. The recruitment, consent, and blood collection procedures are as follows: an STEMI alert is triggered in our institution by acute ST-segment elevation in 2 contiguous leads of the 12-lead electrocardiography (ECG) in the ambulance or immediately upon arrival in the emergency department (ED). Delayed consent was granted for patients presenting with STEMI to avoid interfering with the door-to-balloon time. Each subject had 4 plasma citrate tubes of venous blood drawn within 10 minutes of arriving in the emergency department and before AT A GLANCE COMMENTARY Schmidt RA, et al.
Background
A poorer long-term mortality for patients with non-ST-segment elevation myocardial infarction (NSTEMI) compared with ST-segment elevation myocardial infarction (STEMI) is observed in spite of antiplatelet inhibitor prescription. Unpredictable behavior of platelet inhibitors administered in some patients with myocardial infarction (MI) was previously attributed to differences in absorption and metabolism of antiplatelet drugs.
Translational Significance
This study shows that the platelet phenotype may be fundamentally different in patients with NSTEMI compared with STEMI, with differences in agonist sensitivity and the ability to synthesize and secrete biomarkers. Platelet extracellular-signal-regulated kinase 5 appears to be a central mediator of dysregulated platelet activity during MI in humans, which supports previous observations in murine models.
P2Y12 antagonists were administered. This first sample was used for platelet isolation, and patients were consented within 24 hours of blood draw after coronary angiography. The sample was discarded if the patient declined to enroll. For patients with NSTEMI, subjects were already in the ED or hospital for 1-24 hours and identified by elevated plasma cardiac troponin (plasma value greater than the 99th percentile of a healthy population with a 10% assay coefficient of variation) with concomitant symptoms consistent with cardiac chest pain. Patients with NSTEMI were approached for consent before P2Y12 antagonists were given or coronary angiography was conducted. Each patient was treated with 325-mg aspirin in the ambulance, in the ED, or hospital at least 30 minutes before blood draw. We excluded any patient who could not provide consent, if the patient died, and patients with thrombocytopenia, anemia, or active hematologic malignancies. We also excluded patients who were administered a loading dose of a P2Y12 receptor antagonist in the prehospital setting or the ED. Healthy volunteer subjects were enrolled by answering posted documents at the University of Rochester and were free from antiplatelet medications. We enrolled 60 subjects: 20 healthy subjects aged 20-76 years and 40 patients with acute MI aged 29-86 years (20 with STEMI, 20 with NSTEMI). Patient demographics were recorded in a confidential manner. Platelet function was studied within 1 hour of blood draw. To enhance the clinical relevance of this study, we compared the summed agonist dose-response curves only for platelet signaling pathways for which oral antagonists are available (aspirin for cyclooxygenase inhibition which decreases platelet thromboxane release, U46619 is the agonist used in this study; clopidogrel, ticagrelor, and prasugrel for P2Y12 receptor inhibition, 2-methyl-ADP is the agonist used in this study; vorapaxar for proteaseactivated receptor 1 [PAR1] inhibition; thrombin receptor activator peptide 6 [TRAP] is the agonist used in this study).
Platelet function. For each subject, blood was drawn by a medical professional into citrate plasma tubes and then centrifuged in a tabletop centrifuge at 1100 rpm for 15 minutes. The platelet-rich plasma (PRP) well above the buffy coat was decanted, and the final platelet centrifugation step at 2600 rpm for 5 minutes was conducted with a final concentration of 10 µM PGI2. The final washed platelet pellet from 1 human plasma citrate tube was resuspended in 1000 µL of fresh Tyrode solution, which was diluted 1:20 in fresh Tyrode solution. This was aliquoted into 100 µL of quadruplicate platelet samples and stimulated with 1 µL of each drug concentration. After 15 minutes, 1 µL of labeled CD62P (Pselectin) antibody was incubated in the dark for 30 minutes. This reaction was then stopped by adding 100 µL of 2% formalin to each reaction, and then quantification of platelet surface P-selectin was made possible using an Accuri Flow Cytometer (BD Biosciences) at 10,000 events per sample. Data were then processed through FlowJo (FlowJo, LLC, Ashland, Oregon). Platelet surface P-selectin was quantified in quadruplicate using the geometric mean and then expressed as fold change from baseline to account for differences in experimental condition. For each concentration of drug for each patient, the sample was run in quadruplicate (baseline, 4 increasing doses of agonist = 20 samples per agonist) for each of 3 agonists per patient for 1 patient encounter.
Reagents Biochemistry. Platelet protein studies. Cell lysis and cell protein extraction, sodium dodecyl sulfate polyacrylamide gel electrophoresis, and Western blotting were conducted using buffers and techniques as described previously. 17 Blocking buffer was 3% bovine serum albumin (Sigma-Aldrich) dissolved in Tris-buffered saline at pH 8.0 (Fisher Scientific) with 0.1% Tween-20 (TBS-T) at room temperature for 1 hour. Primary antibody was 1:1000 overnight at 4°C in 3% Bovine Serum Albumin/TBS-T. Secondary antibody (GE Healthcare) was used in a 1:2000 titer in 5% milk/TBS-T for 1 hour at room temperature. Enhanced chemiluminescence reagent used was SuperSignal West Pico (Thermo Scientific) for each antibody. Final autoradiographic films (BioBlot BXR, Laboratory Product Sales, Rochester, New York) were quantified by densitometry using ImageJ software (NIH).
Matrix metalloproteinase activity assay. Platelets were isolated as described previously and placed in 50% (vol/ vol) 2× nondenaturing sample buffer at the following final concentration: 250 mM Tris-HCl, 0.5% SDS, 1% glycerol, 0.05% bromophenol blue for 10 minutes without boiling, and separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (12% bis-acrylamide containing 1 mg/ mL final concentration gelatin within the matrix) at 125 V (constant voltage, room temperature). The gel was renatured by gently rocking in 2.5% Triton X-100 for 30 minutes at room temperature, then decanting, and incubating in fresh zymogram buffer for 12 hours overnight at 37°C. The zymogram buffer was decanted, and the gel was rocked at room temperature for 4 hours in SimplyBlue SafeStain (Invitrogen). Matrix metalloproteinase (MMP) activity was noted by clear bands in the final gel (a reverse image). Total MMP activity in each lane was quantified by densitometry using ImageJ software (NIH).
Immunodepletion of white blood cells from PRP. PRPwas obtained as above, with quality control studies taken to stay above the buffy coat to decrease the number of white blood cell (WBC) contaminants. We used a fluorescein isothiocyanate-tagged CD41 antibody as a plateletspecific marker and a phycoerythrin-tagged CD45 antibody as a WBC-specific marker, using flow cytometry for isolated platelet analysis. The final step of each PRP isolate for agonist stimulation was 100 µL in volume. For quality control, the final PRP isolate was divided into 2 equal volumes, with one-half incubated with a human anti-CD45 antibody to deplete residual WBCs using the MagniSort Human CD45 Depletion Kit (Invitrogen Catalog No.8804-6802-74) according to the manufacturer's instructions. A THP1 cell line, which is known to contain matrix metalloproteinase 9 (MMP9) and CD45, was used as a positive control for WBCs. 20, 21 We noted CD45 but not CD41 immunoreactivity in THP1. We normalized platelet MMP9 protein content to immunoreactive CD41 in CD45-depleted, CD45 (+), and control IgG non-depleted, CD45 (−), PRP. We observed a slight but not significant decrease in platelet MMP9 immunoreactivity (MMP9/ CD41 ratio 1.9 ± 0.51 in depleted vs 2.9 ± 0.86 in nondepleted PRP, P = 0.36).
Immunoassay. Enzyme-linked immunosorbent assays (ELISAs) were conducted according to the manufacturer's instructions using the sandwich ELISA technique. The ELISAs for plasma MMP9 (Catalog No. DY911) and TIMP1 (Catalog No. DY970-05) were purchased from R&D Systems (Minnesota). The ELISA for plasma thromboxane B2 (Catalog No. 501020) was purchased from Cayman Chemicals.
Statistical analysis. Data were analyzed by using GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, California). Dichotomous clinical variables are presented as frequencies. Continuous clinical variables are presented as mean with standard error of the mean, unless otherwise stated. Differences between groups were assessed with analysis of variance for repeated measurements. Where pairwise comparisons between the baseline and the experimental condition could be made, a t test was used. Plasma biomarker data were evaluated by receiver operator characteristic (ROC) curve analysis with performance of the biomarker for predicting the clinical condition reported as area under curve, sensitivity, and specificity with 95% confidence interval. Significance was determined by a P value < 0.05.
RESULTS
Baseline population. The general characteristics of the subjects in this investigation are shown in Table I . Demographic data, clinical variables, and cardiovascular comorbidities were similar between patients with STEMI and NSTEMI, with the notable exception that patients with STEMI had a greater peak cardiac troponin plasma concentration.
Platelet function at the time of STEMI is different from NSTEMI. Using a well-validated method of flow cytometry to detect platelet surface P-selectin expression as an index of platelet activation, 22 we observed a wide range of individual platelet responses to surface receptor agonists for patients presenting with STEMI and NSTEMI in spite treatment with 325-mg aspirin at least 30 minutes before Fig S1) . We found no difference in P2Y12 receptor signaling at any agonist concentration between platelets from patients with STEMI compared with NSTEMI (Fig 1, A) . The platelet thromboxane receptor signaling pathway was more activated in patients presenting with STEMI (Fig 1, B) , whereas the platelet PAR1 signaling pathway was more activated in patients presenting with NSTEMI (Fig 1, C) . Using a transient thromboxane metabolite (thromboxane B2, TxB2) as an indirect plasma marker of cyclooxygenase activity, patients with STEMI and NSTEMI showed a similar plasma concentration of TxB2, suggesting factors that may alter aspirin absorption such as morphine and changes in autonomic activity at the time of MI were similar between groups ( Supplementary Fig. S2 ).
Postreceptor signaling in platelets differs in patients with
STEMI compared with NSTEMI. Consistent with a previous report in mice that platelet ERK5, a redox-activated kinase, promotes dysregulated platelet activity in a murine model of MI, 17 we observed that ERK5 activation occurs in human platelets at the time of MI. Using a phospospecific antibody, which detects the ERK5 activation motif, a mild increase (2.2-fold over baseline) in platelet ERK5 activation was noted in patients presenting with STEMI and a marked increase (4.4-fold over baseline) in NSTEMI. We also observed a concomitant 2.2-fold decrease in platelet ERK5 protein expression in patients presenting at the time of STEMI compared with NSTEMI, likely explaining the difference in activation between groups (Fig 2, A) . Using an inhibitor of ERK5, we could dose-dependently inhibit agonist-induced platelet activation in healthy platelets, which was slightly more efficacious in platelets taken from patients with NSTEMI (Fig 2, B) .
Platelets are enriched in MMPs. 23 MMPs may be important for platelet signaling and tissue remodeling at remote sites, including myocardial infarct extension and myocardial rupture. 17, 24 MMP9 is enriched in the coronary sinus of patients after MI 25, 26 and has been implicated in deleterious cardiac remodeling in murine models of MI, 17, 27 whereas platelet-mediated MMP2 release was reported to occur irrespective of aspirin treatment. 28 Supporting previous studies, we observed that healthy human platelets express only a negligible quantity of MMP9 protein, 29, 30 although MMP9 protein content in platelets persisted after accounting for the possibility of occasional WBC contaminants in PRP (Supplementary Fig S3) . We observed a 3-fold upregulation in MMP9 protein expression in platelets from patients with STEMI and NSTEMI (Fig 3, A) as further evidence of a different platelet phenotype compared with healthy conditions. Interestingly, MMP9 activity by zymography was 9-fold greater in STEMI but only 3-fold greater in NSTEMI than in control platelets (Fig 3, B) . We simultaneously observed the reciprocal trend of less tissue inhibitor of MMP protein 1 (TIMP1) protein expression in platelets from patients with STEMI and NSTEMI compared with control (0.46 ± 0.16, 0.47 ± 0.1, and 0.97 ± 0.17, respectively) (Fig 3, C) . Finally, we detected MMP9 activity in more plasma samples from patients with STEMI than NSTEMI, which corresponded to our observation in platelets (Fig 4,  A and B) .
Platelet-derived biomarkers in the plasma predict MI. Examining plasma, isolated platelets, and aspirated intracoronary thrombus at the time of coronary intervention in a patient with an inferior STEMI, we observed multiple enzymatically active gelatinases, although MMP9 activity appeared to be most prominent in coronary thrombus, aligning with the same band in platelets and plasma (Fig 4, C) . Platelet reactivity in patients with STEMI is different from patients with NSTEMI: All patients were given 325-mg aspirin at least 30 minutes before blood draw. Platelets were isolated and examined basally (0) or after stimulation with agonists for (A) the P2Y12 receptor (ADP), (B) the thromboxane receptor (U46619), and (C) protease-activated receptor 1 (PAR1) for 15 minutes and activation assessed by fluorescence-activated cell sorting by P-selectin expression, mean fluorescence intensity (MFI) ± standard error of the mean (SEM), all performed in quadruplicate in each group, n = 12-17. *P < 0.05 and **P < 0.01 between STEMI and NSTEMI.
We observed a stepwise increase in MMP9 concentration in the plasma of patients with NSTEMI and STEMI, respectively, compared with normal subjects. We also observed a reciprocal decrease in plasma TIMP1 expression in the same subjects (Fig 5) . Using the first blood sample drawn from the patient on arrival, plasma MMP9 predicted STEMI with 90% specificity and 80% sensitivity and NSTEMI with 90% specificity and 50% sensitivity (Fig 6, A) . Moreover, plasma MMP9 could distinguish between patients with STEMI and NSTEMI with 85% specificity and 60% sensitivity, which was superior to cardiac troponin T from the same sample (Fig 6,B) . Thus, MMP9, serving as an early plateletderived biomarker, could be useful in distinguishing MI from other causes of chest pain in an undifferentiated patient presenting with a nonacute ECG, and plasma Fig 2. (A) Platelet ERK5 activation in STEMI and NSTEMI: All patients were given 325-mg aspirin at least 30 minutes before blood draw. Platelets were isolated from healthy volunteer subjects (control) or from patients with STEMI or NSTEMI. ERK5 activation was assessed by Western blotting using a phospho-specific antibody (P-ERK5). A pan-ERK5 antibody was used to detect total ERK5, and the ratio (P-ERK5/ERK5) was used to report ERK5 activity as mean ± standard error of the mean (SEM). *P < 0.05 control vs STEMI, **P = 0.01 control vs NSTEMI, n = 10-13. GAPDH was used as a loading control for normalizing ERK5 expression, *P < 0.05 vs *control, n = 6-9. The molecular weight is indicated in kilodaltons (kDa). (B) ERK5 inhibition prevents platelet activation. All patients were given 325-mg aspirin at least 30 minutes before blood draw. Platelets were isolated from healthy volunteer subjects (control, white) or from patients with NSTEMI (black) and incubated with BIX 02189 (0-100 µM, 30 minutes) before platelet stimulation with TRAP6 (10 µM, 15 minutes). Platelet activation was assessed by fluorescence-activated cell sorting by P-selectin expression, mean fluorescence intensity (MFI) ± SEM, all performed in quadruplicate in each group, n = 4. *P < 0.05 between NSTEMI/TRAP6 and NSTEMI/TRAP6 + BIX 02189 and **P < 0.05 control/TRAP6 and control/TRAP6 + BIX 02189. ERK5, extracellular-signal-regulated kinase 5; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction. cardiac biomarkers that are not yet released or less than the assay detection limit.
DISCUSSION
To our knowledge, this is the first investigation of platelet receptor function and postreceptor signaling comparing patients presenting with STEMI and patients with NSTEMI immediately upon arrival after only aspirin monotherapy and before percutaneous instrumentation. Platelets from patients presenting with STEMI were found to be different from patients with NSTEMI, with residual platelet activation observed after aspirin treatment in both groups, but with different platelet receptor agonist sensitivities and with different postreceptor signaling properties. Platelets from patients with STEMI and NSTEMI were also found to be phenotypically different from platelets in healthy volunteers, with STEMI platelets favoring the thromboxane receptor signaling pathway and NSTEMI platelets favoring the PAR1 pathway. The P2Y12 agonist dose-response curve in platelets from patients with STEMI and NSTEMI was virtually indistinguishable between groups at all concentrations of agonist used. Previous investigations reported plasma microribonucleic acid (miRNA) and platelet ribonucleic acid (RNA) profiles are different in patients presenting with STEMI and NSTEMI. 31, 32 Our study in platelets supports and extends these observations. A phenotypically different platelet population in STEMI compared with NSTEMI may be a hitherto unexplored possibility for the different patient outcomes observed as the recommended antiplatelet therapy for either is the same.
A significant advantage of our study design was the provision of delayed patient consent for blood draw and Platelet biomarker evaluation in STEMI and NSTEMI: All patients were given 325-mg aspirin at least 30 minutes before blood draw. Platelets were isolated from healthy volunteer subjects (control) or from patients with STEMI or NSTEMI. (A) MMP9 protein content was assessed by Western blotting. (B) MMP activity was assessed by gel zymography. (C) TIMP1 protein expression was assessed by Western blotting. GAPDH is a loading control. Protein expression or MMP activity is represented as mean ± standard error of the mean (n = 5-19). *P < 0.05 vs control, **P < 0.01 vs control. The molecular weight is indicated in kilodaltons (kDa). MMP, matrix metalloproteinase; MMP9, matrix metalloproteinase 9; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; TIMP, tissue inhibitor of MMP protein 1. therefore obtaining the blood before loading with a P2Y12 receptor antagonist and before coronary angiography or instrumentation. These factors all contribute significantly to experimental variability with respect to platelet function and biomarker evaluation, they limit interpretation of clinical data, and may contaminate clinical trial design with antiplatelet medications. [33] [34] [35] Because we challenged platelets with surface receptor agonists only for clinically relevant signaling pathways for which oral antagonists are available, we gained insight into which platelet signaling pathways may be important in STEMI and NSTEMI. This opportunity may have been lost had we relied on indirect aggregometry and examination of basal (unstimulated) platelet activation.
Fig 4.
Plasma MMP activity in STEMI and NSTEMI: All patients were given 325-mg aspirin at least 30 minutes before blood draw. Plasma was isolated and (A) MMP activity was assessed by gel zymography and (B) displayed graphically as % active MMP9 detected in plasma (n = 15 samples for STEMI, n = 9 samples for NSTEMI).
(C) Plasma, platelets, or coronary thrombus were examined by zymography in the same patient with an acute inferior STEMI attributed to a right coronary artery aspirated thrombus. MMP9 appears to be the most active gelatinase in these samples. MMP, matrix metalloproteinase; MMP9, matrix metalloproteinase 9; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction. The biological processes involved in platelet activation and thrombosis in STEMI and NSTEMI may be different-a phenomenon that was proposed previously. With STEMI, arterial thrombosis manifests as a flow-limiting occlusion of an epicardial coronary artery caused by plaque rupture, erosion, and infrequently a calcified nodule. 36 Atheroembolism, conversely, is thought to be the signature of platelet activation in NSTEMI and may be a recurrent phenomenon. Recurrent myocardial hypoperfusion events in NSTEMI were previously linked to adverse long-term patient outcomes. 37 By inference, NSTEMI may be a disorder of platelet function, whereas STEMI may be a disorder with an equal contribution of the vasculature and platelets. Hence, it stands to reason that uniformly treating patients with aspirin and a P2Y12 receptor antagonist after STEMI and NSTEMI with the assumption that they are the same biological process might yield different long-term outcomes as reported. 15 Our data indicate no acute differences in signaling through the P2Y12 (ADP) receptor for STEMI and NSTEMI platelets, but preference for PAR1 (TRAP6) signaling in NSTEMI, and preference for the thromboxane signaling pathway (U46619) in STEMI. This observation implies aspirin with or without PAR1 blockade may be beneficial for NSTEMI. The Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes (TRACER) study showed a nonsignificant relative reduction of 8% in the primary end point, but the study employed triple antiplatelet therapy of aspirin, clopidogrel, and vorapaxar with a significant trend toward bleeding. 38 Although it remains unclear whether a trial of aspirin plus a PAR1 antagonist or a PAR1 antagonist alone would change long-term patient outcomes in NSTEMI, a recent study by Wong et al, using a PAR4 antagonist elegantly demonstrated marked platelet inhibition without being blighted by the specter of bleeding diatheses common to PAR1 antagonists. 39 Together, these observations emphasize the importance of returning to the fundamentals of platelet biology and understanding the nuances of platelet signaling to improve patient outcomes.
Thromboxane receptor and PAR1 receptor signaling but not P2Y12 receptor signaling was different in STEMI and NSTEMI platelets in the current investigation. A downstream commonality for PAR1 and thromboxane receptor signaling is stimulating the Gαq G-protein to activate the mitogen-activated protein kinase family member ERK5 in the platelet, which was previously demonstrated in healthy human and murine platelets. 17 Our study supports and complements the literature by showing the platelet PAR1 and thromboxane receptors and downstream ERK5 signaling distinguish STEMI from NSTEMI platelets, but P2Y12 receptor signaling, which was reported not to be a strong ERK5 activator in platelets, does not.
17 ERK5 has been demonstrated to activate platelets, Blood was taken from patients immediately upon presentation with STEMI or NSTEMI and compared with healthy volunteer subjects. Patients with STEMI or NSTEMI were given 325-mg aspirin at least 30 minutes before blood draw. ROC analysis was used to determine the performance of (A) plasma MMP9 from the first blood sample obtained from the patient. *P < 0.0001 predicting STEMI. § P = 0.03 predicting NSTEMI and (B) plasma MMP9 and cTnT in distinguishing between STEMI and NSTEMI, *P = 0.006 for MMP9 between groups and ¶ P = 0.08 for cTnT between groups. AUC, area under curve; cTnT, cardiac troponin T; MMP9, matrix metalloproteinase 9; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.
particularly in environments of redox stress which is typical for MI. 17, 18, 40 These observations propose ERK5 as a potential pharmacologic target of dysregulated platelet activity in thrombotic disease, especially in patients with ongoing ischemic disease as is the case with NSTEMI. ERK5 tends to drive cell cycle progression in nucleated cells, 41, 42 and so the presence in the anucleate platelet suggests a carryover remnant from the precursornucleated megakaryocyte. By inference, ischemic cardiac disease may 'reprogram' bone marrow megakaryocytes to generate dysfunctional platelets with enhanced thrombotic potential as was suggested in peripheral artery disease, diabetes, and atrial fibrillation. 19, 43, 44 Platelets from patients with STEMI and NSTEMI, unlike platelets from healthy subjects, synthesize and likely secrete large quantities of activated MMP9. Platelet MMP activity was previously demonstrated to affect platelet activation and aggregation, whereas post-translational MMP9 modifications including s-nitrosylation and phosphorylation alter MMP9 enzymatic activity and MMP stability. [45] [46] [47] MMPs were also reported to propagate coronary plaque rupture, tissue remodeling, and myocardial infarct expansion. 17, 27, 48, 49 The difference in MMP9 activity in platelets from STEMI compared with NSTEMI, in spite of similar quantities of MMP9 protein and a similar decrease in platelet TIMP1 (inhibitor) content, further suggests different biochemical properties of platelets from each patient population. Platelets are activated before coronary thrombosis and subsequent myocardial necrosis. Platelet-derived biomarkers therefore may be useful in early risk stratification. 50 This notion aligns with a previous study, which showed coronary artery MMP9 concentration at the site of plaque rupture was an independent predictor of STEMI.
26 MMP9 synthesis and activation-at least in part-may be one of the pathophysiological consequences of 'aspirin resistance' or dysregulated platelet activity in the post-MI environment.
Our investigation does have some limitations. The population size, while heterogeneous, was relatively small and will need to be validated in a larger cohort. A small number of patients were taking antiplatelet agents before arrival with MI and we could not determine the true adherence to these agents. This could present as a source of interference in the platelet function studies. Patients with STEMI in our study were immediately and objectively diagnosed by ECG in the prehospital setting or the ED, and the first blood sample was used for platelet function studies. Patients with NSTEMI-as would be expected by relying on a positive cardiac biomarker for the diagnosis-were identified 1-24 hours after presentation and sometimes only after serial blood draws. A difference in the time to diagnose NSTEMI compared with STEMI may theoretically affect platelet function. The contribution of platelets and additional cells such as monocytes and neutrophils to the plasma MMP9 pool measured in our patients as predictive of STEMI and NSTEMI is unclear and will need further investigation.
This translational study demonstrated that receptors and postreceptor signaling properties, as well as platelet reactivity, are different in platelets from patients presenting acutely with STEMI and NSTEMI. The platelet proteome could be exploited to discover biomarkers of prognostic value for MI given that platelet activation precedes coronary thrombosis and myocardial necrosis.
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